822.55
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$823.62
Offen:
$817
24-Stunden-Volumen:
1.76M
Relative Volume:
0.48
Marktkapitalisierung:
$739.75B
Einnahmen:
$49.00B
Nettoeinkommen (Verlust:
$11.11B
KGV:
66.93
EPS:
12.29
Netto-Cashflow:
$-1.27B
1W Leistung:
-6.19%
1M Leistung:
+11.49%
6M Leistung:
+2.10%
1J Leistung:
+11.98%
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
LLY
Lilly Eli Co
|
822.22 | 739.75B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
155.21 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
ABBV
Abbvie Inc
|
195.29 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
![]()
NVO
Novo Nordisk Adr
|
69.23 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
NVS
Novartis Ag Adr
|
113.03 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-12-10 | Fortgesetzt | BofA Securities | Buy |
2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
2024-10-17 | Eingeleitet | Bernstein | Outperform |
2024-09-13 | Fortgesetzt | Citigroup | Buy |
2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-10-20 | Fortgesetzt | UBS | Buy |
2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
2023-07-26 | Bestätigt | Citigroup | Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-05-24 | Bestätigt | BofA Securities | Buy |
2023-05-24 | Bestätigt | UBS | Buy |
2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-03-06 | Eingeleitet | Jefferies | Hold |
2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
2022-09-22 | Hochstufung | UBS | Neutral → Buy |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
2021-12-17 | Eingeleitet | Goldman | Neutral |
2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
2021-12-16 | Bestätigt | BofA Securities | Buy |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
2021-07-27 | Fortgesetzt | Truist | Buy |
2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
2020-09-29 | Eingeleitet | Berenberg | Hold |
2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
2020-04-21 | Herabstufung | UBS | Buy → Neutral |
2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-02-06 | Eingeleitet | Mizuho | Neutral |
2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
2019-05-28 | Eingeleitet | Goldman | Buy |
2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
2019-03-12 | Eingeleitet | JP Morgan | Overweight |
2019-01-23 | Eingeleitet | UBS | Buy |
2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-10-09 | Eingeleitet | Guggenheim | Buy |
2018-10-01 | Bestätigt | SunTrust | Buy |
2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly announces $1.50 Q2 dividend per share - Investing.com
LLY stock news: Eli Lilly Declares $1.50 Quarterly Dividend - paginasiete.bo
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.7% Yield - StreetInsider
Lilly declares second-quarter 2025 dividend - Yahoo Finance
3 No-Brainer Stocks to Buy in May - The Motley Fool
Eli Lilly’s Strategic Adjustments and Growth Prospects Reinforce Buy Rating Despite Setbacks - TipRanks
Eli Lilly First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance
This pill could forever change how people lose weight3 May 2025Time Magazine EuropeReadly | All magazines - Readly | All magazines - one magazine app subscription
Eli Lilly and Company (NYSE:LLY) Q1 2025 Earnings Call Transcript - Insider Monkey
Eli Lilly (LLY) Stock Rating Maintained by UBS Despite Price Tar - GuruFocus
Eli Lilly (NYSE:LLY) Announces Promising Trial Data And Updates 2025 Guidance - Yahoo Finance
UBS cuts Eli Lilly stock target to $1,050, maintains Buy rating - Investing.com UK
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - AOL.com
Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why. - MSN
Cantor Fitzgerald maintains $975 target on Eli Lilly stock By Investing.com - Investing.com India
Cantor Fitzgerald maintains $975 target on Eli Lilly stock - Investing.com
Eli Lilly Stays Strong Despite CVS Dropping Key Drug - Finimize
Leerink sees Eli Lilly stock dip as buying chance, keeps $944 target - Investing.com India
Lilly to participate in Bank of America Securities 2025 Healthcare Conference - Quantisnow
Eli Lilly CFO to Share Strategic Insights at Major Bank of America Healthcare Conference - Stock Titan
Positive Outlook for Eli Lilly & Co. Despite Competitive Challenges - TipRanks
Eli Lilly (LLY) Price Target Reduced by UBS Analyst Despite Stro - GuruFocus
Eli Lilly (LLY) sell-off 'overdone' on CVS move on WegovyLeerink - StreetInsider
Eli Lilly Tackles CVS Health's Cut In Zepbound Coverage - Finimize
Street View: Eli Lilly well positioned in weight-loss market despite CVS's decision - TradingView
Eli Lilly selloff on CVS Wegovy news overdone, says JPMorgan - TipRanks
Eli Lilly & Co: Strong Market Position and Growth Potential Amid Competitive Pressures - TipRanks
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight - GuruFocus
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations - GuruFocus
Eli Lilly (LLY) Faces Market Cap Drop Amid Competitive Pressure - GuruFocus
Eli Lilly (LLY) Prepares for Potential Tariffs on Pharmaceuticals - GuruFocus
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal - MSN
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge - Reuters
Friday Five – Pharma's tariff-proofing playbook, Novo slims Lilly's lead, vaccine policy shakeup…and more - FirstWord Pharma
Obesity Drug Price Wars Heating Up as CVS Picks Novo Over Lilly - Bloomberg.com
Lilly Cuts Earnings Guidance on Research Charges, Shares Fall - Bloomberg.com
Eli Lilly (LLY) Stock: Shares Tumble 10% Despite 45% Revenue Surge in Q1 2025 - CoinCentral
Eli Lilly and Company (LLY) Stock Price, News, Quote & History - Yahoo Finance
CVS Drops Lilly’s Zepbound from Preferred Coverage in Novo Win - Bloomberg.com
Eli Lilly Shares Tumble 10% After Q1 Earnings Miss Wall Street Estimates - Yahoo
Eli Lilly (LLY) Gains WHO Support for Obesity Drug Zepbound - GuruFocus
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge By Reuters - Investing.com
Is Eli Lilly and Company (LLY) the Best Growth Stock to Buy for the Next 3 Years? - Insider Monkey
Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade' - Yahoo Finance
Why Eli Lilly (LLY) Stock Is Nosediving - Yahoo Finance
Eli Lilly, Microsoft Lead Market Cap Stock Movers on Thursday By Investing.com - Investing.com Nigeria
Eli Lilly Earnings: Solid Performance Overshadowed by Novo’s Obesity Coverage Win - Morningstar
Eli Lilly (NYSE:LLY) Reports Strong Q1 Growth Despite Lowered 2025 EPS Guidance - Yahoo Finance
Eli Lilly, Microsoft Lead Market Cap Stock Movers on Thursday - Investing.com
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):